|
128 Companies |
|
121 Products |
|
121 Products |
|
104 Mechanisms of Action |
|
7 Trials |
|
1812 News |
|
| «12...1718192021222324252627...3637» |
- Phase classification, Enrollment change: Proton Beam Therapy to Treat Esophageal Cancer (clinicaltrials.gov) - Aug 22, 2014
P1, N=40, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P=N/A --> P1 | N=20 --> 40
- Clinical: Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=50, Recruiting, Sponsor: University of Miami
- |||| Dexilant (dexlansoprazole) / Takeda
Enrollment open: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation (clinicaltrials.gov) - Aug 19, 2014
P4, N=150, Recruiting, Sponsor: Takeda
Phase classification: P=N/A --> P1 | N=20 --> 40 Not yet recruiting --> Recruiting
- | imipramine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn (clinicaltrials.gov) - Aug 19, 2014
P3, N=83, Completed, Sponsor: Mahidol University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=40 --> 83 | Trial primary completion date: May 2013 --> Sep 2013
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed, Surgery, Metastases: Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction (clinicaltrials.gov) - Aug 19, 2014
P2, N=70, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | N=40 --> 83 | Trial primary completion date: May 2013 --> Sep 2013 Completed --> Active, not recruiting
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Aug 15, 2014
P2, N=40, Not yet recruiting, Sponsor: Heikki Joensuu
- Trial completion, Enrollment change, Trial primary completion date: Imaging Study Compare 4DCT Image (clinicaltrials.gov) - Aug 15, 2014
P1, N=52, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting Recruiting --> Completed | N=36 --> 52 | Trial primary completion date: Jul 2016 --> Aug 2014
- K-CAB Tab (tegoprazan) / RaQualia, Sebela
Trial completion: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (clinicaltrials.gov) - Aug 8, 2014
P2, N=206, Completed, Sponsor: CJ HealthCare Corporation
Recruiting --> Completed | N=36 --> 52 | Trial primary completion date: Jul 2016 --> Aug 2014 Recruiting --> Completed
- ||||||| esomeprazole / Generic mfg.
Trial completion: Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) (clinicaltrials.gov) - Aug 8, 2014
P3, N=1398, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Surgery: STAR Registry: Registry to Compare Two Surgical Treatments for GERD (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=500, Recruiting, Sponsor: American Gastroenterological Association
- sirolimus / Generic mfg.
Trial primary completion date: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Aug 7, 2014
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2016
- Clinical: Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=12, Recruiting, Sponsor: Massachusetts General Hospital
- |||| cendakimab (CC-93538) / AbbVie, BMS
Enrollment open: HEROES: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis (clinicaltrials.gov) - Aug 6, 2014
P2, N=90, Recruiting, Sponsor: Receptos, Inc.
Trial primary completion date: Sep 2014 --> Sep 2016 Not yet recruiting --> Recruiting
- Trial completion, Metastases: Perception Prognosis, Goals of Treatment, and Communication (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=50, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
Trial primary completion date, Surgery: Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer (clinicaltrials.gov) - Aug 4, 2014
P2, N=36, Active, not recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Trial primary completion date: Mar 2013 --> Dec 2015
- Trial primary completion date: Imaging Study Compare 4DCT Image (clinicaltrials.gov) - Aug 1, 2014
P1, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2013 --> Dec 2015 Trial primary completion date: Jul 2015 --> Jul 2016
- Enrollment change, Trial termination, Trial primary completion date, Surgery, Metastases: Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 1, 2014
P2, N=29, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Jul 2015 --> Jul 2016 N=192 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Aug 2013; company withdrew interest
- Herceptin (trastuzumab) / Roche, tesevatinib (KD019) / Sanofi
New P1 trial, Metastases: KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer (clinicaltrials.gov) - Aug 1, 2014
P1, N=0, Withdrawn, Sponsor: New York University School of Medicine
- New P1 trial: Study to Image the Esophagus Using the OFDI Capsule (clinicaltrials.gov) - Jul 30, 2014
P1, N=54, Recruiting, Sponsor: Massachusetts General Hospital
- Trial completion, Trial primary completion date, Biopsy: Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus (clinicaltrials.gov) - Jul 30, 2014
P1, N=22, Completed, Sponsor: Massachusetts General Hospital
N=192 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Aug 2013; company withdrew interest Recruiting --> Completed | Trial primary completion date: Oct 2015 --> May 2014
- cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Trial primary completion date: nabPCESCC: Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage ?-? Esophageal Cancer Patients (clinicaltrials.gov) - Jul 30, 2014
P2, N=35, Completed, Sponsor: Zhejiang Cancer Hospital
Recruiting --> Completed | Trial primary completion date: Oct 2015 --> May 2014 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2012
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Trial completion: Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 30, 2014
P0, N=25, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2012 Active, not recruiting --> Completed
- Biomarker, Enrollment change, Trial withdrawal: Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation (clinicaltrials.gov) - Jul 29, 2014
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=100 --> 0 | Not yet recruiting --> Withdrawn
- sorafenib / Generic mfg.
Trial primary completion date, Metastases: Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 25, 2014
P2, N=35, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Jun 2014 --> Jun 2015
- esomeprazole / Generic mfg.
Trial primary completion date: BRAVO Study for Functional Dyspepsia (clinicaltrials.gov) - Jul 23, 2014
P4, N=130, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- || Dexilant (dexlansoprazole) / Takeda
Trial primary completion date, IO biomarker: Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? (clinicaltrials.gov) - Jul 23, 2014
P4, N=60, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: May 2014 --> Dec 2014
- Enrollment closed, Trial primary completion date: FGISP-RCT: Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: May 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Dec 2015
- saracatinib (AZD0530) / AstraZeneca
Enrollment change, Metastases: Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 18, 2014
P2, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2013 --> Dec 2015 N=35 --> 21
- Trial primary completion date: POEM Trial: Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM) (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=150, Recruiting, Sponsor: Katholieke Universiteit Leuven
N=35 --> 21 Trial primary completion date: Jan 2016 --> Jan 2018
- Clinical: Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=56, Completed, Sponsor: St. John Health System, Michigan
- Trial primary completion date: Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer (clinicaltrials.gov) - Jul 12, 2014
P2, N=163, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Jan 2016 --> Jan 2018 Trial primary completion date: Apr 2014 --> Apr 2016
- |||| Revanex (revaprazan) / Yuhan
Trial completion, P2 data: Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD) (clinicaltrials.gov) - Jul 12, 2014
P2, N=149, Completed, Sponsor: Yuhan Corporation
Trial primary completion date: Apr 2014 --> Apr 2016 Active, not recruiting --> Completed
- |||| esomeprazole / Generic mfg.
Trial completion: Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis (clinicaltrials.gov) - Jul 12, 2014
P2, N=154, Completed, Sponsor: Yuhan Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Soltamox (tamoxifen citrate) / Jazz
Enrollment open: Tamoxifen to Treat Barrett's Metaplasia (clinicaltrials.gov) - Jul 10, 2014
P0, N=30, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Three Methods Used in the Diagnosis of EER in Children With OME (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=24, Completed, Sponsor: University Hospital Ostrava
- Gastrocrom (cromolyn) / Viatris
Trial primary completion date: Cromolyn Detection of Silent Aspiration (clinicaltrials.gov) - Jul 8, 2014
P1, N=15, Not yet recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Apr 2015
- Trial primary completion date: Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=220, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jul 2014 --> Apr 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Vectibix (panitumumab) / Amgen, Takeda
Trial termination, Combination therapy: EOXP: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=17, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Terminated; Closed due to slow accrual
- Gastrocrom (cromolyn) / Viatris
Trial initiation date, Trial primary completion date: Cromolyn Detection of Silent Aspiration (clinicaltrials.gov) - Jul 8, 2014
P1, N=15, Not yet recruiting, Sponsor: University of California, San Francisco
Recruiting --> Terminated; Closed due to slow accrual Initiation date: Jul 2013 --> Jun 2014 | Trial primary completion date: Jul 2014 --> Apr 2015
- Vectibix (panitumumab) / Amgen, Takeda
Enrollment change, Trial termination, Combination therapy: EOXP: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=17, Terminated, Sponsor: Massachusetts General Hospital
Initiation date: Jul 2013 --> Jun 2014 | Trial primary completion date: Jul 2014 --> Apr 2015 N=30 --> 17 | Recruiting --> Terminated; Closed due to slow accrual
- | ONO-8539 / Ono Pharma
Trial completion: A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers (clinicaltrials.gov) - Jul 8, 2014
P1, N=20, Completed, Sponsor: Ono Pharmaceutical Co. Ltd
N=30 --> 17 | Recruiting --> Terminated; Closed due to slow accrual Active, not recruiting --> Completed
- | esomeprazole / Generic mfg.
Enrollment open: A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases (clinicaltrials.gov) - Jul 3, 2014
P3, N=50, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change, Metastases: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=15 --> 28
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Enrollment change, Metastases: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
N=15 --> 28 Recruiting --> Completed | N=15 --> 28
- Trial primary completion date: HRM RTSIO: Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=15, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed | N=15 --> 28 Trial primary completion date: Apr 2014 --> Jan 2014
- Enrollment change: HRM RTSIO: Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=15, Completed, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Apr 2014 --> Jan 2014 N=20 --> 15
- Trial completion, Enrollment change, Trial primary completion date: HRM RTSIO: Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=15, Completed, Sponsor: University Hospital, Bordeaux
N=20 --> 15 Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Apr 2014 --> Jan 2014
- lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial termination, Metastases: GastroLap: Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (clinicaltrials.gov) - Jul 2, 2014
P2, N=76, Terminated, Sponsor: National Center for Tumor Diseases, Heidelberg
Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Apr 2014 --> Jan 2014 Active, not recruiting --> Terminated; Changes of SoC for third line therapy resulting in poor recruitment
- aspirin / Generic mfg., esomeprazole / Generic mfg.
Enrollment change: Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus (clinicaltrials.gov) - Jul 2, 2014
P2, N=122, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Changes of SoC for third line therapy resulting in poor recruitment N=168 --> 122
- aspirin / Generic mfg., esomeprazole / Generic mfg.
Trial completion: Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus (clinicaltrials.gov) - Jul 2, 2014
P2, N=122, Completed, Sponsor: National Cancer Institute (NCI)
N=168 --> 122 Active, not recruiting --> Completed